Skip to content
Screener

Aclaris Therapeutics ACRS Q4 2025 Annual earnings

Reported February 26, 2026 · Before market open

Revenue$1.3MMiss by $776.1K
EPS-$0.16Miss by $0.01
Revenue estimate$2.1M
EPS estimate-$0.15

Next report

Nov 5, 2026 (in a month)
Revenue estimate$1.3M
EPS estimate-$0.16

Financials

Q4 2025

Income statement

See full
Revenue$1.3M-85.9%
Gross profit$763.0K-91.0%
Operating income-$22.7M+77.2%
Net income-$19.8M+79.5%
EPS (diluted)-$0.16+86.8%

Balance sheet

See full
Cash & equivalents$20.0M-18.8%
Total debt$2.1M-18.6%
Total equity$103.1M-33.7%
Total assets$160.5M-27.2%

Cash flow

See full
Operating cash flow-$13.1M-46.9%
CapEx$24.0K—
Free cash flow-$13.2M-47.2%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$326.12M+22.9%
Enterprise value$308.28M+26.6%
P/S41.7×+27.5×

Profitability

See full
Gross margin73.3%-11.8pp
Operating margin-975.9%+393pp
Net margin-829.6%+177pp
FCF margin-603.4%—

Returns & leverage

See full
Return on equity-50.2%-14.5pp
Debt / equity0×0.0×
Current ratio3.4×-0.6×

Segments

By product

See full
Dermatology Therapeutics$795.0K—

FAQ

When did Aclaris Therapeutics report Q4 2025 earnings?
Aclaris Therapeutics (ACRS) reported Q4 2025 earnings on February 26, 2026 before market open.
What were Aclaris Therapeutics's Q4 2025 revenue and EPS?
Aclaris Therapeutics reported revenue of $1.3M and eps of $-0.16 for Q4 2025.
Did Aclaris Therapeutics beat estimates in Q4 2025?
Revenue missed the consensus estimate of $2.1M by $776.1K. EPS missed the consensus estimate of $-0.15 by $0.01.
How did Aclaris Therapeutics's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 85.9% from $9.2M a year earlier and eps declined 60.0% from $-0.10.
Where can I find Aclaris Therapeutics's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001104659-26-020070) and the 10-K periodic report (0001104659-26-020540) directly on SEC EDGAR. The filing index links above go to sec.gov.